GlassScriptPhysician profile
Natalie Alane Marshall
NPI 1366445470
$2,534.81
in general payments reported to CMS, 2019-2025
32 companies · $60.81 in 2025
The $60.81 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,280 · 2020: $47.80 · 2021: $101 · 2022: $45.51 · 2025: $60.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $60.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $60.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $241.88 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $223.11 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $201.18 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $196.81 | 2019 | |
| Janssen Biotech, INC. | $176.97 | 2019-2021 | |
| Astellas Pharma US INC | $155.16 | 2019 | |
| Merck Sharp & Dohme LLC | $145.73 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $123.31 | 2019 | |
| Genentech USA, INC. | $115.02 | 2019-2021 | |
| Seagen INC. | $88.80 | 2019 | |
| Celgene Corporation | $86.28 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $86.00 | 2019 | |
| Tesaro, INC. | $80.52 | 2019 | |
| Clovis Oncology, INC. | $79.62 | 2019 | |
| Amgen INC. | $62.81 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $59.62 | 2019 | |
| Tempus Ai, INC | $42.74 | 2025 | Xt Cdx |
| Abbvie INC. | $42.46 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $40.45 | 2019 | |
| Genzyme Corporation | $37.90 | 2019 | |
| Acrotech Biopharma INC. | $25.90 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $25.30 | 2019 | |
| Alexion Pharmaceuticals, INC. | $24.27 | 2019 | |
| Lilly USA, LLC | $23.93 | 2019 | |
| Daiichi Sankyo INC. | $23.92 | 2019 | |
| Eisai INC. | $22.92 | 2019 | |
| Exelixis INC. | $22.22 | 2019 | |
| Sanofi-Aventis U.S. LLC | $21.72 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.61 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $17.45 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Janssen Pharmaceuticals, INC | $9.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Marshall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.